Physiomics Announces License Agreement with Eli Lilly
News Apr 06, 2009
Physiomics, the Oxford, UK based systems biology company has announced that it has signed a license agreement with Eli Lilly and Company.
Under the terms of the agreement, Physiomics will license to Lilly a customized version of its ModelPlayer for in silico simulations of unspecified anticancer drugs and Lilly will have the option to purchase additional licenses.
According to Physiomics, its ModelPlayer is a stand-alone simulation platform used for in-house model development that can be out-licensed to partners to allow them to perform their own simulations using Physiomics’ models. It incorporates a range of features necessary for developing and calibrating models and simulating anticancer drugs.
Dr Christophe Chassagnole, COO of Physiomics, said: ‘We are delighted with the continued interest shown by Lilly in Physiomics’ technology. We hope that the capability for Lilly scientists to directly use Physiomics’ models will strengthen the quality of the interactions within our ongoing research collaborations. This is also an important commercial and technical milestone for Physiomics as this is the first time that we have out-licensed our technology.’
How do Poison Frogs Protect Themselves Against Their Own Neurotoxin?News
Scientists are a step closer to resolving a related head-scratcher, how do these frogs keep from poisoning themselves?READ MORE
Unchained Labs Unveils LEA 9 Software Making Workflows EasyNews
Unchained Labs, the life sciences company that’s all about getting biologics researchers the right tool for the job, released its LEA 9 software, making Freeslate and Junior automation systems way more accessible.READ MORE